BioCentury | Apr 14, 2021
Management Tracks

CEO succession at Amarin; plus Lilly, IGM, Jounce and more

...be replaced by Karim Mikhail,  SVP and head of commercial for Europe at the cardiovascular company.Eli Lilly and Co....
...Partners as a partner. Rivassou previously served as investment director at ISAI. BC Staff Biogen Inc. Amarin Corp. plc Eli Lilly and Co. IGM...
BioCentury | Apr 14, 2021
Emerging Company Profile

Jaguar to deploy $139M series B toward broad gene therapy pipeline

...but shifted gears after being introduced to Eli Lilly and Co....
...N/ANumber of employees: ~30Funds raised: $180 millionInvestors: Eli Lilly and Co....
BioCentury | Apr 12, 2021
Politics, Policy & Law

Cavazzoni brings competence, continuity as CDER director

...where she also served patients in a mood disorder clinic. In August 2000, she joined Eli Lilly and Co....
...the center should adopt lessons learned from the experience. Steve Usdin U.S. Food and Drug Administration (FDA) Pfizer Inc. Eli Lilly and Co. Sanofi Biogen...
BioCentury | Apr 10, 2021
Product Development

Baricitinib improves on SOC survival benefit in hospitalized COVID patients

...unmet need” in the pandemic, Anabela Cardoso, Eli Lilly and Co....
...INCB28050 (Former compound #), baricitinib (Generic), Olumiant (Other) Eli Lilly and Co. covid-19 covid19 cov19count cov19count...
BioCentury | Apr 7, 2021
Product Development

April 6 Quick Takes: MGH to pilot AZ digital platform; plus NorthShore-GoPath prostate cancer risk test, baricitinib delay at FDA, MTEM setback

...for baricitinib sNDAFDA pushed back by three months the PDUFA date for an sNDA for baricitinib from Eli Lilly and Co....
BioCentury | Apr 3, 2021
Product Development

Digging beyond the headlines at AACR 2021

...to regulatory submission, the most watched moves at this year’s AACR are the return of Eli Lilly and Co....
BioCentury | Apr 1, 2021
Deals

Gilead again partners with AbCellera, forging multitarget deal that draws on biotech’s growing tool kit

...the larger deals AbCellera has entered, roughly in the same league as its partnerships with Eli Lilly and Co....
BioCentury | Apr 1, 2021
Product Development

Lilly-Vir mAb cocktail could expand treatment to low-risk COVID-19 patients

...outpatients. Three mAb therapies have emergency use authorization to treat COVID-19 in high-risk outpatients: bamlanivimab from Eli Lilly and Co....
...monotherapy based on data from the Phase II/III COMET-ICE study. Sandi Wong bamlanivimab, LY-CoV555 (LY3819253) VIR-7831 (GSK4182136) Vir Biotechnology Inc. Eli Lilly and Co. GlaxoSmithKline...
BioCentury | Mar 30, 2021
Product Development

Novel preclinical therapies for COVID-19: Data Byte

...blood of recovered patients. The first such mAb therapy to receive emergency use authorization, bamlanivimab from Eli Lilly and Co....
BioCentury | Mar 27, 2021
Regulation

March 26 Quick Takes: ADCs from Astellas-Seagen, Gilead under EMA review; plus Pfizer-Lilly, BrainStorm and Ilya

...TNBC. FDA adcomm votes 19-1 against REMS for OA therapy from Pfizer, LillyPfizer Inc. (NYSE:PFE) and Eli Lilly and Co....
...sacituzumab govitecan (hRS7-SN-38, IMMU-132) tanezumab (PF-4383119, RN 624, RN-624, ri 624) Astellas Pharma Inc. Seagen Inc. Gilead Sciences Inc. Pfizer Inc. Eli Lilly and Co. Nectin-4...
Items per page:
1 - 10 of 6247
BioCentury | Apr 14, 2021
Management Tracks

CEO succession at Amarin; plus Lilly, IGM, Jounce and more

...be replaced by Karim Mikhail,  SVP and head of commercial for Europe at the cardiovascular company.Eli Lilly and Co....
...Partners as a partner. Rivassou previously served as investment director at ISAI. BC Staff Biogen Inc. Amarin Corp. plc Eli Lilly and Co. IGM...
BioCentury | Apr 14, 2021
Emerging Company Profile

Jaguar to deploy $139M series B toward broad gene therapy pipeline

...but shifted gears after being introduced to Eli Lilly and Co....
...N/ANumber of employees: ~30Funds raised: $180 millionInvestors: Eli Lilly and Co....
BioCentury | Apr 12, 2021
Politics, Policy & Law

Cavazzoni brings competence, continuity as CDER director

...where she also served patients in a mood disorder clinic. In August 2000, she joined Eli Lilly and Co....
...the center should adopt lessons learned from the experience. Steve Usdin U.S. Food and Drug Administration (FDA) Pfizer Inc. Eli Lilly and Co. Sanofi Biogen...
BioCentury | Apr 10, 2021
Product Development

Baricitinib improves on SOC survival benefit in hospitalized COVID patients

...unmet need” in the pandemic, Anabela Cardoso, Eli Lilly and Co....
...INCB28050 (Former compound #), baricitinib (Generic), Olumiant (Other) Eli Lilly and Co. covid-19 covid19 cov19count cov19count...
BioCentury | Apr 7, 2021
Product Development

April 6 Quick Takes: MGH to pilot AZ digital platform; plus NorthShore-GoPath prostate cancer risk test, baricitinib delay at FDA, MTEM setback

...for baricitinib sNDAFDA pushed back by three months the PDUFA date for an sNDA for baricitinib from Eli Lilly and Co....
BioCentury | Apr 3, 2021
Product Development

Digging beyond the headlines at AACR 2021

...to regulatory submission, the most watched moves at this year’s AACR are the return of Eli Lilly and Co....
BioCentury | Apr 1, 2021
Deals

Gilead again partners with AbCellera, forging multitarget deal that draws on biotech’s growing tool kit

...the larger deals AbCellera has entered, roughly in the same league as its partnerships with Eli Lilly and Co....
BioCentury | Apr 1, 2021
Product Development

Lilly-Vir mAb cocktail could expand treatment to low-risk COVID-19 patients

...outpatients. Three mAb therapies have emergency use authorization to treat COVID-19 in high-risk outpatients: bamlanivimab from Eli Lilly and Co....
...monotherapy based on data from the Phase II/III COMET-ICE study. Sandi Wong bamlanivimab, LY-CoV555 (LY3819253) VIR-7831 (GSK4182136) Vir Biotechnology Inc. Eli Lilly and Co. GlaxoSmithKline...
BioCentury | Mar 30, 2021
Product Development

Novel preclinical therapies for COVID-19: Data Byte

...blood of recovered patients. The first such mAb therapy to receive emergency use authorization, bamlanivimab from Eli Lilly and Co....
BioCentury | Mar 27, 2021
Regulation

March 26 Quick Takes: ADCs from Astellas-Seagen, Gilead under EMA review; plus Pfizer-Lilly, BrainStorm and Ilya

...TNBC. FDA adcomm votes 19-1 against REMS for OA therapy from Pfizer, LillyPfizer Inc. (NYSE:PFE) and Eli Lilly and Co....
...sacituzumab govitecan (hRS7-SN-38, IMMU-132) tanezumab (PF-4383119, RN 624, RN-624, ri 624) Astellas Pharma Inc. Seagen Inc. Gilead Sciences Inc. Pfizer Inc. Eli Lilly and Co. Nectin-4...
Items per page:
1 - 10 of 6247